Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche - COVID-19, Global partnership for a global health emergency

10/27/2021 | 04:07am EST

COVID-19 has profoundly impacted the world we live in. Within months, national lockdowns, business closures and social distancing measures had changed life as we knew it, while a novel coronavirus ravaged even the furthest corners of global society. We had to adapt to this new, fast-paced and ever-evolving environment. This meant we needed an unprecedented drive in innovation across the globe; one that was only possible through tireless collaboration.

Around the world, industry, academia, governments, and non-profit organisations joined forces to fight the pandemic. These partnerships have been paramount in combatting the disease and investigating options that meet the varying needs of patients, healthcare professionals and society at large.

At Roche, we have a vital responsibility as a healthcare company to help overcome the pandemic. We're working to support countries in managing COVID-19 by helping to track the spread of the virus, providing tools that help diagnose patients so that they may receive the appropriate treatments and are able to return to their normal lives' more quickly. Employees from across the business are still heavily involved in the COVID-19 response as it continues to evolve. Our aim is to help reduce the spread of the virus, and ultimately to reduce the need for patients to be hospitalised.

We're fast approaching two years since the first cases of a novel coronavirus were reported. We've asked leading researchers, Roche experts and healthcare professionals to reflect on the great strides that have been made in the effort to tackle the pandemic during crucial timepoints. We hope to learn from them as we begin to navigate our new normal, together.

Contact:

Toll Free: 1800-833-3374

T: 96192 13075

E-mail: india.medinfo@roche.com.

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ROCHE HOLDING AG
08:48aChugai's Actemra, RoActemra Approved by the European Commission to Treat Patients with ..
AQ
07:01aNOVEL APPROACH IN THE STUDY OF THE C : extensive biochemical measurement of biomarkers fou..
AQ
12/08UK Initiates Study of COVID-19 Therapies from Merck & Co., Roche-Regeneron
MT
12/08REMINDER : Invitation to Roche's virtual event on key hematology data presented at ASH 202..
PU
12/08CHMP Recommends EU Approval of Chugai's Actemra, RoActemra to Treat Patients with Sever..
AQ
12/07Roche, Genentech Join Recursion Pharmaceuticals to Advance Neuroscience, Oncology Medic..
MT
12/07Recursion Pharmaceuticals Sets Drug-Discovery Pact With Roche, Genentech
DJ
12/07EU Authorizes Roche's Arthritis Medicine for Treatment of Severe COVID-19
MT
12/07PTC Therapeutics, Inc. - Evrysdi Distinguished by Two Prestigious Awards for Outstandin..
AQ
12/07EU Approves Roche's Actemra/RoActemra Against Severe Covid-19
DJ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 197 M 67 318 M 67 318 M
Net income 2021 15 305 M 16 565 M 16 565 M
Net cash 2021 3 944 M 4 269 M 4 269 M
P/E ratio 2021 20,4x
Yield 2021 2,51%
Capitalization 304 B 329 B 329 B
EV / Sales 2021 4,82x
EV / Sales 2022 4,71x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 372,90 CHF
Average target price 388,97 CHF
Spread / Average Target 4,31%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Pascale Schmidt Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG20.68%329 493
JOHNSON & JOHNSON4.42%432 641
PFIZER, INC.39.64%288 501
NOVO NORDISK A/S73.12%256 630
ELI LILLY AND COMPANY45.17%221 499
ABBVIE INC.13.74%215 452